Delivery Order SPE2DB22D9353-SPE2DB25FX2EG
- Not listed
- On August 11, 2025, the Defense Logistics Agency (DLA) awarded a delivery order valued at $8,622.72 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The delivery order covers 120 capsules of Xtandi 40 mg, an oncology treatment medication, under a firm fixed-price contract with an ultimate completion date of August 12, 2025. This award was issued without a set-aside designation, allowing DMS Pharmaceutical Group to compete...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, awarded on September 3, 2025, with an ultimate completion date of September 4, 2025, was issued without a set-aside designation. The award represents a single delivery order issued under DMS...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,934.05 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). The contract, effective August 12, 2025 with completion by August 13, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. This award represents a single transaction under DMS Pharmaceutical Group's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count). This firm fixed-price delivery order, issued on July 22, 2025, is expected to be completed by July 23, 2025, and carries no set-aside designation. The award falls under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a $4,311.35 firm fixed-price delivery order from the Defense Logistics Agency (DLA) on July 18, 2025, for 120 capsules of Xtandi 40 mg. The delivery order is not designated as a set-aside contract and carries an ultimate completion date of July 21, 2025. This award represents a single delivery transaction executed under DMS Pharmaceutical Group's larger Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,622.72 by the Defense Logistics Agency on August 25, 2025, for the supply of Xtandi 40 mg capsules (120-count). The contract carries no set-aside designation and is scheduled for completion by August 26, 2025. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the...
- The Defense Logistics Agency awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). The delivery order, issued on July 16, 2025, with an ultimate completion date of July 17, 2025, carries firm fixed-price terms and represents a direct procurement with no set-aside designation. This award falls under DMS Pharmaceutical Group's...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $4,169.59 by the Defense Logistics Agency (DLA) on July 22, 2025. The contract, which carries no set-aside designation, calls for the delivery of 60 tablets of Xtandi 80 mg, an oncology medication used in cancer treatment. This delivery order represents one of many pharmaceutical supply orders issued under DMS...
- The Defense Logistics Agency awarded a delivery order valued at $8,622.72 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, issued on September 8, 2025, with an ultimate completion date of September 9, 2025, carries no set-aside designation. The award is issued under DMS Pharmaceutical Group's existing single-award Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $25,868.10 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, on September 4, 2025. This firm fixed-price delivery order covers the supply of Xtandi 40 mg capsules (120-count units), an oncology medication used in prostate cancer treatment. The contract carries no set-aside designation and is scheduled for ultimate completion by September 5, 2025, with...
- SPE2DB22D9353Indefinite Delivery Contract
- SPE2DB22D9353-SPE2DB25FX2EGDelivery Order
On September 5, 2025, the Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $43,113.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The delivery order covers the supply of 120 capsules of Xtandi 40 mg, an oncology medication used in cancer treatment. This award was issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with DLA under the SPE2DB program, which is valued at approximately $500 million through November 2026. The contract carries no set-aside designation, allowing the vendor to compete directly in the open federal marketplace. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with a robust portfolio of delivery orders from the DLA covering a comprehensive range of medications and medical supplies. The company's core business involves distributing branded and generic prescription drugs, biologics, and medical consumables to military and federal healthcare facilities nationwide. This particular delivery order for Xtandi exemplifies the company's specialization in providing specialized pharmaceutical products, including oncology treatments, to support the Department of Defense's medical supply needs across its healthcare system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $43.1k | 9/5/25 |